For families and clinicians navigating the already agonizing calculus of pediatric heart transplantation, donor organ quality decisions carry life-or-death weight. A new signal from a large national registry suggests that accepting a heart from a COVID-19-positive donor may carry a meaningful long-term mortality penalty for children — one that does not become visible until well past the first year post-transplant.
Drawing on the Standard Transplant Analysis and Research (STAR) database, investigators identified 1,978 pediatric primary heart transplant recipients between 2020 and 2024. Sixty of those received hearts from donors who tested COVID-19-positive within seven days of procurement. After 1:5 propensity matching to control for demographics and baseline clinical factors, short-term survival appeared equivalent: no statistically significant mortality difference emerged at 6 months, 1 year, or 18 months. The divergence materialized at the 2-year mark and widened by year three, with cumulative survival of 71.5% in COVID-19-positive donor recipients versus 86.3% in controls — a matched hazard ratio of approximately 2.19. Notably, the mortality risk was further amplified when donor-recipient height mismatch was present, suggesting a potential interaction between organ sizing and underlying donor pathology.
The delayed emergence of the mortality gap is scientifically important and clinically underappreciated. SARS-CoV-2 is known to cause myocardial inflammation, microvascular injury, and persistent endothelial dysfunction even in donors who appear hemodynamically stable. The 14.8 percentage-point survival gap at three years is substantial by transplant standards, yet it was invisible for the first 18 months — the window during which most center-level outcome benchmarking occurs. This raises a genuine concern that current post-transplant surveillance protocols may be inadequately capturing late graft dysfunction. Key limitations include the relatively small COVID-positive cohort (n=60), the observational design precluding causal inference, and the inability to adjust for viral variant, donor COVID-19 disease severity, or vaccination status. The finding is hypothesis-generating rather than definitive, but its magnitude warrants prospective validation and should inform informed-consent conversations with pediatric transplant families.